Oryzon Genomics SA Email Format

Biotechnology ResearchCatalonia, Spain51-200 Employees

Oryzon Genomics (ISIN: ES0167733015) is a clinical-stage biopharmaceutical company and a European leader in epigenetics, with a strong focus on personalized medicine for central nervous system (CNS) disorders and oncology/hematology. Founded in 2000 and headquartered in Barcelona, Spain, Oryzon brings together a highly experienced team accross Barcelona, Boston, and New Jersey.

The Company’s clinical portfolio is built around two differentiated LSD1 inhibitors. Iadademstat, its oncology/hematology program, is being evaluated in multiple Phase I and II clinical trials, with very promising efficacy signals in first-line acute myeloid leukemia, including a 100% overall response rate (ORR) presented at ASH 2025, with additional data expected at EHA 2026. 

Vafidemstat, its lead CNS candidate, is in clinical development across neuropsychiatric indications, including aggression in borderline personality disorder (Phase III in preparation), negative symptoms of schizophrenia (ongoing Phase IIb) and aggression in autism spectrum disorder (ASD), including genetically defined populations such as Phelan-McDermid syndrome (Phase II in preparation).

Beyond LSD1, Oryzon is expanding its pipeline to new targets such as HDAC6, with ORY-4001 nominated for potential development in neurological diseases including ALS and CMT.

Oryzon also leverages a robust biomarker platform supporting precision medicine approaches. The Company is listed on the Spanish Stock Exchange (ORY) and has attracted specialized international investors from the United States and Europe.

Sign up for free to view info

Company overview Employee directory